University College London is a top-rated university in the UK for research strength in the new Research Excellence Framework 2014. It is part of three of the 11 biomedical research centres established by the NHS in England. Research within UCL is organised into large, cross-disciplinary communities that span UCL and our partner organisations, fostering interaction and collaboration. The Clinical Pharmacology & Therapeutics Group contributes to UCL Personalised Medicine Domain, which harnesses the breadth and depth of the personalised medicine research activity taking place across the institution and its partner hospitals, supporting the delivery of innovative patient-targeted medicines and therapies.
UCL has a strong expertise in innovative research methodologies based on synthesis of evidence like modelling & simulation and extrapolation approach. This will enable our Consortium to include this relevant part of the project complementing what done by CVBF and IPCZD. UCL also has a long-standing collaboration in the framework of other paediatric research projects and networks (e.g. GRiP – Global Research in Paediatrics Network of Excellence, DEEP – Deferiprone Evaluation in Paediatrics, GAPP – GAbapentin in Paediatric Pain and TEDDY – Network of Excellence for Paediatric Clinical Research). Moreover, UCL has a consolidated and internationally-recognised experience in training activities, considering that it is one of the most prestigious universities in the world.
It is a member of 3 of the 11 biomedical research centres established by the NHS in England. It is also a founding member of UCL Partners, the largest academic health science centre in Europe with a turnover of approximately £2 billion.
The development of pharmacokinetic and pharmacokinetic pharmacodynamic models to support dosing algorithms involves dedicated databases and modelling and simulation software. The Clinical Pharmacology & Therapeutics Group has availability of server-based applications for data analysis. In addition, processes and procedures have been developed to allow the implementation of research protocols and reporting according to good clinical practice guidelines.
Research IT infrastructure is supported by UCL’s Research Computing Platform Services, a dedicated group which assists research groups with programming and access to high performance computing platforms.
Licences and dedicated user training are available for the most common software programmes required for Modelling & Simulation, namely, NONMEM (Icon Solutions, USA), Berkeley Madonna (University of California at Berkeley, ISA), WinBUGS (MRC Biostatistics Unit, UK), R (R Project, Austria) and R-Studio (DMCA, USA).